Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 102 of the 103 references it cites were found in a registry or an index.

Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis

Vollenweider, F · 1997 · Neuropsychopharmacology

Abstract

The effects of the indolehallucinogen psilocybin, a mixed 5-HT2 and 5-HT1 agonist, on regional cerebral glucose metabolism were investigated in 10 healthy volunteers with PET and [F-18]-fluorodeoxyglucose (FDG) prior to and following a 15- or 20-mg dose of psilocybin. Psychotomimetic doses of psilocybin were found to produce a global increase in cerebral metabolic rate of glucose (CMRglu) with significant and most marked increases in the frontomedial and frontolateral cortex (24.3%), anterior cingulate (24.9%), and temporomedial cortex (25.3%). Somewhat smaller increases of CMRglu were found in the basal ganglia (18.5%), and the smallest increases were found in the sensorimotor (14.7%) and occipital cortex (14.4%). The increases of CMRglu in the prefrontal cortex, anterior cingulate, temporomedial cortex, and putamen correlated positively with psychotic symptom formation, in particular with hallucinatory ego disintegration. The present data suggest that excessive 5-HT2 receptor activation results in a hyperfrontal metablic pattern that parallels comparable metabolic findings associated with acute psychotic episodes in chronic schizophrenics and contrasts with the hypofrontality in chronic schizophrenic patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(96)00246-1

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 103 references

Cited by

  • Psychedelics

    Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762

    “Ettrup et al. (2010) evaluated [11C]CIMBI-5 [N-(2methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine] (25I-NBOMe) as an agonist radioligand for PET imaging of 5-HT2A receptors.”
    BackgroundResultInfluential
  • Meditation states and traits: EEG, ERP, and neuroimaging studies.

    Cahn, B. R., & Polich, J. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.2.180 · Cited by 1,734

    “…and depersonalization phenomena (Farrer et al., 2003; Farrer & Frith, 2002; Kircher & David, 2003; MacDonald & Paus, 2003; Mathew et al., 1999; Sierra, Lopera, Lambert, Phillips, & David, 2002; Simeon et al., 2000; Vollenweider, 1998; Vollenweider & Geyer, 2001; Vollenweider et al., 1997).”
  • Hallucinogens

    Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211

  • Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

    Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206

    “These changes were correlated with measures of psychological state and consistent with potential neurobiological substrates of major mental illnesses.(20) In one recent study, 36 healthy volunteers received a high dose (30 mg/70 kg) of psilocybin with no sustained deleterious physiological or psychological effects.”
    Result
  • Human hallucinogen research: guidelines for safety

    Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203

    “findings that have supported hallucinogens as a model of at least certain aspects of acute psychosis (Gouzoulis-Mayfrank, Heekeren et al., 1998; Vollenweider et al., 1997; Vollenweider and Geyer, 2001; Gouzoulis-Mayfrank et al., 2005, 2006).”
    Background

See all 467

Metadata

Authors
Vollenweider, F.
Affiliations
University Hospital Zurich (CH)
Corresponding author
Vollenweider, F
Venue
Neuropsychopharmacology
Published
1997-05
Volume
16
Issue
5
Pages
357-372
ISSN
0893-133X (ISSN-L)
OpenAlex
W2048509938
Cited by
444
References
103
Citations by year
2026: 16 · 2025: 25 · 2024: 27 · 2023: 40 · 2022: 35 · 2021: 22 · 2020: 25 · 2019: 9 · 2018: 16 · 2017: 21 · 2016: 30 · 2015: 18 · 2014: 18 · 2013: 10 · 2012: 11
FWCI
10.52
Type
journal article
Language
en
Open access
closed
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • University of Bern
  • National Research Foundation
  • Paul Scherrer Institut
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
Keywords
psilocybin, psychosis, brain glucose metabolism, 5-HT1 receptors, prefrontal cortex, anterior cingulate cortex, putamen, psychotomimetic effects, schizophrenia, hypofrontality
MeSH terms
Adult, Animals, Basal Ganglia, Brain, Deoxyglucose, Female, Fluorine Radioisotopes, Frontal Lobe, Hallucinogens, Humans, Male, Psilocybin, Psychological Tests, Psychoses, Substance-Induced, Radioactive Tracers, Tomography, Emission-Computed, Serotonin Receptor Agonists, Fluorodeoxyglucose F18

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. https://app.cochat.ai/papers/10.1016/s0893-133x(96)00246-1
The paper
Vollenweider, F. (1997). Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology. https://doi.org/10.1016/s0893-133x(96)00246-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.